We report the first documented case of an erythroid/B-cell biphenotypic acute leukemia. The most recent World Health Organization criteria for biphenotypic or mixed phenotype acute leukemia does not include an erythroid/lymphoid phenotype. This case may help establish erythroid/B-cell biphenotypic acute leukemia as a distinct entity.
The patient was a 73-year old man who saw his primary care physician (PCP) for bruising. The patient had noticed bruising on his arms, legs and abdomen and was experiencing fatigue for the past week. He denied any bleeding. A complete blood count (CBC) was sent. He had followed up with his PCP 2 days later with the CBC showing thrombocytopenia and anemia with normal leukocyte count ( Table 1) .
The PCP referred the patient to the emergency room for further evaluation. The patient's past medical history was significant for hypertension, hyperlipidemia, allergies, eczema and osteoarthritis. His social history was significant for immigrating to the United States 22 years ago from China. In China, he worked as an organic chemist and reported multiple occupational exposures such as mouth pipetting. Family history and review of systems were noncontributory. Physical exam revealed bruising with no lymphadenopathy or hepatosplenomegaly.
Laboratory tests included a basic metabolic panel, liver function test and coagulopathy panel, which were all unremarkable. A complete blood count with differential (CBCD) confirmed the presence of thrombocytopenia and anemia with a 100-cell leukocyte differential showing 9% blasts ( Table 1) .
The peripheral smear showed large blasts that had round to oval nuclei ( Figure 1 ). The nuclear chromatin was finely dispersed with some interspersed clumped chromatin. One to two prominent nucleoli were present. The cytoplasm was darkly basophilic with occasional cytoplasmic vacuoles. No Auer rods were present. Neutrophil morphology included occasional pelgeroid nuclei with normal cytoplasmic granularity. Erythrocyte, platelet, monocyte and lymphocyte morphology were unremarkable.
The patient remained stable during his hospital course and had a bone marrow aspirate (BMA) and bone marrow biopsy (BMB). The BMA was sent for a differential, flow cytometry and cytogenetics.
The BMA smears were hypercellular and overwhelmingly composed of blasts ( Figure 2 ). The bone marrow blasts resembled proerythroblasts with round nuclei, finely dispersed chromatin, multiple prominent nucleoli and deeply basophilic cytoplasm. The blasts also had multiple, coalescing cytoplasmic vacuoles. A 200-cell differential showed 77% blasts and 16% erythroid precursor cells. No Auer rods were present. No dysplastic features such as multinucleation, nuclear blebbing or megaloblastoid changes were seen in the erythroid series. There were no ringed sideroblasts present on iron stain. No dysplastic changes were seen in the myeloid or megakaryocytic series.
Flow cytometry showed blasts accounting for 60% of cellularity and expressing CD45, HLA-DR, glycophorin A and CD10 ( Figure 3 ). There was weak, partial expression for CD34 and CD19. There was no expression of myeloid antigens (CD13, CD33, CD64, CD117), monocyte antigen CD14, megakaryocyte antigen CD41, T-cell antigens (CD2, CD3, CD5, CD7, CD4, CD8) or mature B-cell antigens (kappa or lambda immunoglobulin light chain).
The BMB showed a hypercellular marrow with 100% cellularity to fat ratio ( Figure 4 ). The marrow was almost entirely composed of mononuclear cells that were arranged in a diffuse Figure 1 Peripheral blood smear showed large blasts with round to oval nuclei, finely dispersed chromatin, prominent nucleoli and deeply basophilic cytoplasm with vacuoles (Wright-Giemsa, Â 1000). and discohesive pattern. The mononuclear cells had large nuclei with vesicular chromatin and one to two prominent nucleoli. They had scant cytoplasm with indistinct cell borders. Multiple mitotic figures were identified. There was increased reticulin present on special stain. Immunohistochemistry showed the large mononuclear cells to have positive cell membrane staining for CD45 (LCA) and cytoplasmic staining for CD10 ( Figure 5 ). About 50% of the cells had positive nuclear staining for TdT. There was weak punctate cytoplasmic staining for CD22 in about 20% of the large mononuclear cells. The large mononuclear cells had no staining for myeloid antigens (myeloperoxidase, CD117), hemoglobin, megakaryocyte antigen Factor VIII, T-cell antigens (CD3, CD5), early B-cell antigen pax-5, mature B-cell antigens (CD20, CD79a) and plasma cell antigen CD138.
Cytogenetics showed a normal male karyotype 46(X,Y) in 20 cells from a 24 and 48-h unstimulated cell culture. However, fluorescent in situ hybridization (FISH) showed monosomy 7 in 22% (22/101) of cells using the D7S486 probe for 7q31 and D7Z1 probe for chromosome 7 centromere (Figure 6 ). FISH showed no evidence bcr-abl1 or MLL gene rearrangement or deletion. 
Letters to the Editor
Polymerase chain reaction (PCR) from peripheral blood showed an immunoglobulin heavy chain (IgH) gene rearrangement (Figure 7) . No T-cell receptor gamma chain (TCRg) gene rearrangement was identified.
By morphology, this case appears to be a pure erythroid leukemia or acute myeloid leukemia (AML) M6b based on the predominance of blasts that resemble proerythroblasts. These proerythroblast-like blasts constituted 77% of bone marrow cellularity and in combination with the later erythroid precursor cells constituted 93% of cellularity. The later erythroid precursor cells constituted a spectrum of differentiation and included basophilic, polychromatophilic and orthochromatophilic erythroblasts. The immunophenotype of these blasts were positive for glycophorin A by flow cytometry and negative for myeloid antigens, monocytic antigen, megakaryocytic antigens and T-cell antigens by both flow cytometry and immunohistochemistry.
However, these blasts were positive for CD10 and weakly positive for CD19 by flow cytometry. They were also positive for TdT and CD10 and weakly positive for CD22 by immunohistochemistry. They were negative for CD20, CD79a and pax-5 by immunohistochemistry. The immunophenotype is consistent with an early B-cell differentiation. Based on these findings, a diagnosis of an erythroid/B-cell biphenotypic acute leukemia was made.
The patient was readmitted and was started on 7 þ 3 cytarabine and daunorubicin induction chemotherapy. A day 14 BMA and BMB showed an ablated marrow with no residual leukemia. Flow cytometry confirmed that there was no evidence of residual leukemia. The patient successfully completed induction chemotherapy without consolidation, and 6 months later remains remission free.
The acute leukemias of ambiguous lineage has been recently revised by the World Health Organization (WHO). 1 These group of leukemias include those that show no differentiation, those that have two distinct blast populations of different lineages (bilineal) and those that have a single blast population that possess antigens of different lineages (biphenotypic). 1 The current WHO guideline refers to the bilineal and biphenotypic leukemias as mixed phenotype acute leukemia (MPAL). 1 The diagnosis of MPAL is based on immunophentotype with preference for flow cytometry, however immunohistochemistry can be used. 1 Molecular evidence for differentiation such as IgH and TCR gene rearrangement is currently not used for lineage assignment.
The current WHO guideline for a biphenotypic leukemia has requirements for the presence of specific antigens. 1 Myeloid lineage assignment requires either the demonstration of MPO (by flow cytometry, immunohistochemistry or cytochemistry) or monocytic differentiation (with the presence of at least two of Figure 5 Immunohistochemistry showed cell membrane staining for CD45 (LCA), cytoplasmic staining for CD10, nuclear staining for TdT and weak punctate cytoplasmic staining for CD22 ( Â 1000 magnification). Letters to the Editor the following markers: nonspecific esterase, CD11c, CD14, CD64 and lysozyme).
1 T-cell lineage assignment requires the demonstration of cytoplasmic or surface CD3.
1 B-cell lineage assignment can be made by the presence of either strong or weak CD19.
1 Strong CD19 requires the presence of one whereas weak CD19 requires the presence of two of the following additional markers: CD10, cytoplasmic CD22 and CD79a. 1 Currently there have been no erythroid/lymphoid or megakaryocytic/lymphoid biphenotypic leukemia reported to date.
1 It has been proposed that cells with erythroid and megakaryocytic differentiation capacity are the earliest to branch off from the pluripotent hematopoeitic stem cell. 2 After this division point, the hematopoietic progenitor cell has myeloid, B-cell and T-cell differentiation capacities. 2 The WHO does not entirely deny the existence of an erythroid/lymphoid or megakaryocytic/lymphoid biphenotypic leukemia and acknowledges that their current guidelines would not include such entities. 1 There have been few cases of erythroid leukemia showing cross-lineage B-cell antigen expression. There have been no cases of acute erythroid leukemia expressing TdT, CD22, CD19, CD20 or CD79a. However, there have been two cases of leukemia cell lines with an erythroid phenotype showing aberrant CD10 expression. 3, 4 The first case of cross-lineage CD10 expression involves RM10, an erythroid cell line that was established from a chronic myelogenous leukemia (CML) patient in blast crisis. 3 The second case of cross-lineage CD10 expression involves HSM-911, a cell line that was established from an AML patient. 4 The HSM-911 cell line was transfected with p210bcr-abl by electroporation and then acquired glycophorin A and CD10 expression. 4 The fact that there have been no in vivo cases of acute erythroid leukemia showing multiple B-cell antigen expression supports the idea that an erythroid/B-cell biphenotypic leukemia does not exist. Conversely there have been no cases of acute lymphoid leukemia (ALL) expressing glycophorin A or hemoglobin.
Molecular evidence of lymphoid differentiation has not been used as criteria for the diagnosis of biphenotypic leukemia. IgH gene rearrangement has been commonly seen in biphenotypic leukemias. 5, 6 However, a significant proportion of AML have also shown IgH gene rearrangement. 5, 6 One group proposes using gene rearrangement studies as a criteria for lymphoid lineage assignment in biphenotypic leukemias based on correlation between multiple B-cell antigen coexpression and IgH gene rearrangement. 6 There have been several case reports [6] [7] [8] and a case series 9 noting the presence of a Philadelphia chromosome in biphenotypic leukemias with an IgH gene rearrangement. All these case reports [6] [7] [8] and the case series 9 note that these biphenotypic leukemias were acute leukemias that were de novo and not arising from a previous CML. It has been proposed that bcr-abl expression may facilitate somatic mutations of lineage determining genes. 10 We report the first documented case of an erythroid/B-cell biphenotypic acute leukemia. According to the current WHO criteria for a B-cell lineage assignment, our case fulfills those requirements. However, the WHO criteria for biphenotypic leukemia only include myeloid, monocytic, B-cell and T-cell lineages. Because there has been no cases of an erythroid/ lymphoid or megakaryocytic/lymphoid leukemia, the criteria for erythroid and megakaryocytic lineage assignment for biphenotypic leukemias has not been established. We report this case, which may help establish criteria and bring recognition to a previously unrecognized erythroid/B-cell biphenotypic acute leukemia entity.
